Detalhe da pesquisa
1.
Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial.
AIDS Res Ther
; 11: 39, 2014.
Artigo
Inglês
| MEDLINE | ID: mdl-25926858
2.
The DIANA Study: Continued Access to Darunavir/Ritonavir (DRV/r) and Long-Term Safety Follow-Up in HIV-1-Infected Pediatric Patients Aged 3 to < 18 Years.
Drug Saf
; 44(4): 439-446, 2021 04.
Artigo
Inglês
| MEDLINE | ID: mdl-33367975
3.
Etravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of age.
AIDS
; 35(9): 1413-1421, 2021 07 15.
Artigo
Inglês
| MEDLINE | ID: mdl-33831904
4.
Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials.
AIDS Res Hum Retroviruses
; 36(1): 48-57, 2020 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31516033
5.
Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients.
AIDS
; 34(5): 707-718, 2020 04 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31833849
6.
Bioequivalence of the Once-Daily Single-Tablet Regimen of Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Compared to Combined Intake of the Separate Agents and the Effect of Food on Bioavailability.
Clin Pharmacol Drug Dev
; 8(4): 480-491, 2019 05.
Artigo
Inglês
| MEDLINE | ID: mdl-30412360
7.
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.
Antiviral Res
; 170: 104543, 2019 10.
Artigo
Inglês
| MEDLINE | ID: mdl-31279073
8.
Correction to: Evaluation of Cardiovascular Disease Risk in HIV1-Infected Patients Treated with Darunavir.
Drugs R D
; 18(3): 249-250, 2018 09.
Artigo
Inglês
| MEDLINE | ID: mdl-30079430
9.
Evaluation of Cardiovascular Disease Risk in HIV-1-Infected Patients Treated with Darunavir.
Drugs R D
; 18(3): 199-210, 2018 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-29992490
10.
Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.
Lancet HIV
; 5(1): e23-e34, 2018 01.
Artigo
Inglês
| MEDLINE | ID: mdl-28993180
11.
A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients.
AIDS
; 32(11): 1431-1442, 2018 07 17.
Artigo
Inglês
| MEDLINE | ID: mdl-29683855
12.
Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial.
SAGE Open Med
; 5: 2050312116686482, 2017.
Artigo
Inglês
| MEDLINE | ID: mdl-28382208
13.
Assessment of etravirine resistance in HIV-1-infected paediatric patients using population and deep sequencing: final results of the PIANO study.
Antivir Ther
; 21(4): 317-27, 2016.
Artigo
Inglês
| MEDLINE | ID: mdl-26566161
14.
Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationships of Etravirine in HIV-1-Infected, Treatment-Experienced Children and Adolescents in PIANO.
J Clin Pharmacol
; 56(11): 1395-1405, 2016 11.
Artigo
Inglês
| MEDLINE | ID: mdl-27060341
15.
Darunavir/cobicistat once daily for the treatment of HIV.
Expert Rev Anti Infect Ther
; 13(6): 691-704, 2015 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-25962100
16.
Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients: week 48 results of the ARIEL trial.
Pediatr Infect Dis J
; 34(5): e132-7, 2015 May.
Artigo
Inglês
| MEDLINE | ID: mdl-25719453
17.
Week 48 results of a Phase IV trial of etravirine with antiretrovirals other than darunavir/ritonavir in HIV-1-infected treatment-experienced adults.
J Int AIDS Soc
; 17(4 Suppl 3): 19783, 2014.
Artigo
Inglês
| MEDLINE | ID: mdl-25397527
18.
Efficacy and safety of darunavir/ritonavir at 48 weeks in treatment-naïve, HIV-1-infected adolescents: results from a phase 2 open-label trial (DIONE).
Pediatr Infect Dis J
; 33(9): 940-5, 2014 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-25361024
19.
Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers.
J Clin Pharmacol
; 54(8): 949-57, 2014 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-24644095
20.
Bioequivalence of a darunavir/cobicistat fixed-dose combination tablet versus single agents and food effect in healthy volunteers.
Antivir Ther
; 19(6): 597-606, 2014.
Artigo
Inglês
| MEDLINE | ID: mdl-24964392